Short- and long-term effects of fluticasone furoate/vilanterol in exercising asthmatic adolescents: A randomized and open label trial.
Administration, Inhalation
Adolescent
Albuterol
/ administration & dosage
Androstadienes
/ administration & dosage
Asthma
/ drug therapy
Benzyl Alcohols
/ administration & dosage
Bronchodilator Agents
/ administration & dosage
Child
Chlorobenzenes
/ administration & dosage
Double-Blind Method
Drug Combinations
Exercise Test
Female
Forced Expiratory Volume
/ drug effects
Humans
Male
Nebulizers and Vaporizers
Prospective Studies
Time Factors
Treatment Outcome
Relvar
exercise challenge test
exercise-induced asthma
exercise-induced bronchoconstriction
fluticasone furoate (FF)/vilanterol (VI)
salbutamol
Journal
Basic & clinical pharmacology & toxicology
ISSN: 1742-7843
Titre abrégé: Basic Clin Pharmacol Toxicol
Pays: England
ID NLM: 101208422
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
22
06
2021
received:
29
04
2021
accepted:
13
07
2021
pubmed:
7
8
2021
medline:
4
2
2022
entrez:
6
8
2021
Statut:
ppublish
Résumé
Relvar® (fluticasone furoate [FF]/vilanterol [VI]) is a once-daily inhaler with bronchodilator effect lasting 24 h. Our aim was to investigate the short- and long-term effects of FF/VI on exercise-induced asthma (EIA) in adolescents. Ninety-three adolescent asthmatics aged 12-18 years were referred for evaluation of EIA. Following a positive exercise challenge test (ECT), 22/44 were allocated to a single administration of salbutamol (400 μg) and 22/44 to FF/VI (92/22 μg) in a double-blind method. Thirty-five subjects were reassessed by repeat ECT 30-60 days of FF/VI. Median FEV FF/VI is effective in reversing EIA after 15 min in adolescents and in protecting EIA after 30-60 days in adolescents. Larger studies are needed to assess the effect of FF/VI on EIA.
Substances chimiques
Androstadienes
0
Benzyl Alcohols
0
Bronchodilator Agents
0
Chlorobenzenes
0
Drug Combinations
0
fluticasone furoate-vilanterol trifenatate
0
Albuterol
QF8SVZ843E
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
369-375Informations de copyright
© 2021 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd.
Références
Godfrey S, Springer C, Noviski N, Maayan C, Avital A. Exercise but not methacholine differentiates asthma from chronic lung disease in children. Thorax. 1991;46(7):488-492.
Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. Am J Respir Crit Care Med. 2000;161(1):309-329.
Hallstrand TS, Leuppi JD, Joos G, et al. ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing. Eur Respir J. 2018;52(5):1801033.
Sano F, Solé D, Naspitz CK. Prevalence and characteristics of exercise-induced asthma in children. Pediatr Allergy Immunol. 1998;9(4):181-185.
do Amaral LM, Moratelli L, Palma PV, Leite ICG. The quality of life of Brazilian adolescents with asthma: associated clinical and sociodemographic factors. J Asthma. 2014;51(6):660-666.
Fedele DA, Janicke DM, Lim CS, Abu-Hasan M. An examination of comorbid asthma and obesity: assessing differences in physical activity, sleep duration, health-related quality of life and parental distress. J Asthma. 2014;51(3):275-281.
Global Initiative for Asthma. Global strategy for asthma management and prevention, 2021. Accessed June 7, 2021. www.ginasthma.org
Miller MR, Hankinson J, Brusasco V, Burgos F, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
Quanjer PH, Borsboom GJJM, Brunekreef B, et al. Spirometric reference values for white European children and adolescents: Polgar revisited. Pediatr Pulmonol. 1995;19(2):135-142.
Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2021;128(1):4-8.
de Aguiar KB, Anzolin M, Zhang L. Global prevalence of exercise-induced bronchoconstriction in childhood: a meta-analysis. Pediatr Pulmonol. 2018;53(4):412-425.
Pierson WE. Exercise-induced bronchospasm in children and adolescents. Pediatr Clin North am. 1988;35(5):1031-1040.
Syed YY. Fluticasone furoate/vilanterol: a review of its use in patients with asthma. Drugs. 2015;75(4):407-418.
Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013;344(1):218-230.
Weiler JM, Nathan RA, Rupp NT, Kalberg CJ, Emmett A, Dorinsky PM. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Ann Allergy Asthma Immunol. 2005;94(1):65-72.
Machado D, Pereira C, Tavares B, Loureiro G, Segorbe-Luís A. Airways hyperresponsiveness to different inhaled combination therapies in adolescent asthmatics. Eur Ann Allergy Clin Immunol. 2012;44(1):12-17.
Lazarinis N, Jørgensen L, Ekström T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax. 2014;69(2):130-136.
Martin N, Weiler JM, Pearlman D, et al. Fluticasone furoate/vilanterol versus fluticasone propionate in patients with asthma and exercise-induced bronchoconstriction. J Asthma. 2020;57(4):431-440.
Rosethorne EM, Bradley ME, Kent TC, Charlton SJ. Functional desensitization of the β2 adrenoceptor is not dependent on agonist efficacy. Pharmacol Res Perspect. 2015;3(1):1-13.
Bonini M, Permaul P, Kulkarni T, et al. Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide. Am J Respir Crit Care Med. 2013;188(12):1407-1412.